Abstract：【Objective】 To investigate the relationship between serum insulin-like growth factor-1 (IGF-1), interleukin-1α (IL-1α) levels and the efficacy of neoadjuvant chemotherapy (NCT) in patients with non-small cell lung cancer (NSCLC). 【Methods】 Eighty-seven NSCLC patients admitted to two hospitals received NCT for two cycles. Multivariate logistic regression analysis was used to evaluate whether serum IGF-1 and IL-1α were independent risk factors affecting the efficacy of NCT. Receiver operating characteristic (ROC) curve was used to evaluate the predictive value of serum IGF-1 and IL-1α for the efficacy of NCT. 【Results】After treatment, 7 patients achieved complete remission, 39 patients achieved partial remission, and they were included in the effective group; 37 patients had stable disease and 4 patients had progressive disease, and they were included in the ineffective group. The proportion of patients receiving targeted therapy in the effective group was higher than that in the ineffective group (P<0.05), and the levels of IGF-1 and IL-1α were lower than those in the ineffective group (P<0.05). Multivariate logistic regression analysis showed that IGF-1 and IL-1α were independent risk factors affecting the efficacy of NCT (P<0.05), and targeted therapy was an independent protective factor affecting the efficacy of NCT (P<0.05). ROC curve analysis showed that IGF-1 and IL-1α had certain predictive value for the efficacy of NCT, with area under the curve (AUC) of 0.756 and 0.734 respectively. When predicting efficacy of combined therapy for the two predictors, the AUC reached 0.917. 【Conclusion】Serum IGF-1 and IL-1α levels are independent factors influencing the efficacy of NCT in patients with NSCLC, and they have important predictive value for the efficacy of NCT. The predictive effect is higher when the two factors are combined.
阎丽, 严亚军. 非小细胞肺癌患者血清IGF-1、IL-1α水平与新辅助化疗临床疗效的关系[J]. 医学临床研究, 2023, 40(10): 1529-1532.
YAN Li, YAN Yajun. The Relationship between Serum IGF-1, IL-1α Levels and the Efficacy of Neoadjuvant Chemotherapy in Patients with Non-small Cell Lung Cancer. JOURNAL OF CLINICAL RESEARCH, 2023, 40(10): 1529-1532.
[1] 魏玉磊, 崔玉环, 董跃华, 等. 新辅助化疗对ⅢA~N2期肺癌淋巴结转移率的影响及预后生存分析[J].中华医学杂志, 2021, 101(4):259-264. [2] 孙鑫, 门玉, 惠周光. ⅢA~N2期非小细胞肺癌新辅助治疗的研究现状[J].中华放射肿瘤学杂志, 2020, 29(1):61-64. [3] GAUDREAU P O, NEGRAO M V, MITTCHELL K G, et al. Neoadjuvant chemotherapy increases cytotoxic T cell, tissue resident memory T cell, and B cell infiltration in resectable NSCLC[J].J Thorac Oncol,2021, 16(1):127-139. [4] TANG H, BAI Y, PAN G, et al. Interleukin-6 and insulin-like growth factor-1 synergistically promote the progression of NSCLC[J].Autoimmunity,2018, 51(8):399-407. [5] YANG Z, SCHOOLING C M, KWOK M K. Mendelian randomization study of interleukin (IL)-1 family and lung cancer[J].Sci Rep,2021, 11(1):17606-17616. [6] 支修益, 石远凯, 于金明. 中国原发性肺癌诊疗规范(2015年版)[J].中华肿瘤杂志, 2015, 37(1):67-78. [7] ABDEI-RAHMAN O. Validation of the AJCC 8th lung cancer staging system among patients with small cell lung cancer[J].Clin Transl Oncol,2018, 20(4):550-556. [8] AJONA D, ORTIZ-ESPINOSA S, LOZANO T, et al. Short-term starvation reduces IGF-1 levels to sensitize lung tumors to PD-1 immune checkpoint blockade[J].Nat Cancer,2020, 1(1):75-85. [9] ZHENG X, LU G, YAO Y, et al. An autocrine IL-6/IGF-1R loop mediates EMT and promotes tumor growth in non-small cell lung cancer[J].Int J Biol Sci,2019, 15(9):1882-1891. [10] JARADEH M, CURRAN B, POULIKIDIS K, et al. Inflammatory cytokines in robot-assisted thoracic surgery versus video-assisted thoracic surgery[J].J Thorac Dis,2022, 14(6):2000-2010. [11] ABBATE A, TOLDO S, MARCHETTI C, et al. Interleukin-1 and the Inflammasome as therapeutic targets in cardiovascular disease[J].Circ Res,2020, 126(9):1260-1280. [12] SCHUNK S J, TRIEM S, SCHMIT D, et al. Interleukin-1α is a central regulator of leukocyte-endothelial adhesion in myocardial infarction and in chronic kidney disease[J].Circulation,2021, 144(11):893-908. [13] NICOLAS A M, PESIC M, ENGEL E, et al. Inflammatory fibroblasts mediate resistance to neoadjuvant therapy in rectal cancer[J].Cancer Cell,2022, 40(2):168-184. [14] CAMIDGE D R, DOEBELE R C, KERR K M. Comparing and contrasting predictive biomarkers for immunotherapy and targeted therapy of NSCLC[J].Nat Rev Clin Oncol,2019, 16(6):341-355.
2023, Vol. 40 
